The British O&P association published an economic case for investment. Here is what that kind of argument is built to do.

The British Association of Prosthetics and Orthotics announced this week that it had commissioned an independent economic analysis examining the case for increased investment in O&P services across the United Kingdom. The announcement appeared in The O&P EDGE.

That framing, “independent economic analysis,” is not neutral language. It is the language of a professional body building a policy dossier. What the report will argue matters less, at this stage, than why the profession reached for economic evidence to make the case in the first place.

What BAPO is and why it is doing this

BAPO is the professional association representing prosthetists and orthotists working in the United Kingdom. It sets professional standards, represents members, and functions as a public-facing advocate for the field. When BAPO commissions an independent analysis, it is not producing research for its own sake. It is producing evidence designed to be placed in front of NHS England commissioners, the Department of Health and Social Care, and parliamentary health committees.

The distinction matters because UK O&P access works differently than it does in the United States. The majority of prosthetic and orthotic services in the UK are delivered through NHS contracts. There is no insurance carrier to negotiate with, no CMS prior-authorization threshold to fight through, no competitive bidding round to survive. The NHS sets the budget; NHS commissioners decide what services are purchased and at what volume; NHS trusts and independent service providers deliver the care. A patient needing an orthosis is not navigating a coverage determination; they are waiting in a queue whose length depends on how much resource their NHS commissioner has allocated to that service.

That structure means the policy pressure point is different. You cannot change access by changing a coverage rule. You change access by changing how NHS England and the DHSC prioritize O&P in the budget, which requires persuading budget holders that the investment is worth making. That is exactly what an independent economic analysis is built to do.

What the economic argument for O&P investment looks like

The standard structure of health-economic arguments for prosthetic and orthotic investment has been laid out in multiple studies over the past two decades. The core case runs as follows: inadequate or delayed O&P care increases downstream NHS costs at a rate that exceeds the cost of the provision itself.

For amputees, the evidence includes longer inpatient stays following delayed prosthetic fitting, higher rates of secondary complications in people who do not achieve functional mobility, and, particularly for patients with dysvascular or diabetic etiology, who represent the majority of new lower-limb amputees, increased risk of contralateral limb loss and cardiovascular events that generate hospitalizations at substantial cost. The argument is that the NHS is not saving money by underfunding prosthetics; it is deferring cost into a more expensive category.

For orthotics, the argument is structurally similar. Delayed assessment and provision for people with progressive neurological or musculoskeletal conditions is associated with falls, fractures, and accelerated loss of independent mobility. Each of those outcomes generates NHS costs (inpatient episodes, social care referrals, rehabilitation) that dwarf the orthosis that might have been provided earlier.

None of this is a novel argument. It is a well-documented framework, and it has been used to make the O&P investment case in multiple health systems. What it requires, to be useful in budget negotiations, is a number attached to a specific health system with specific workforce and demand data. That is what “independent economic analysis” means in practice: someone has run those calculations for the NHS.

The context in which the report lands

The UK O&P workforce has faced documented recruitment and retention pressures for several years. The number of registered prosthetists and orthotists in the UK has not grown proportionally to the demand generated by an ageing population and rising rates of dysvascular amputation and neurological limb conditions. NHS waiting times for orthotic services, particularly non-urgent referrals, have been a persistent point of concern through the pandemic recovery period and beyond.

The report enters this context. An independent analysis that quantifies the gap between current UK O&P provision and clinically adequate provision, and attaches a cost to that gap, becomes a resource that commissioners can use to justify budget decisions. It also becomes a resource that individual clinicians and BAPO members can use when making arguments inside NHS trusts.

Whether a particular economic analysis moves actual funding depends on factors the report cannot control. The NHS is not operating in a period of easy expansion. Competing priorities are numerous. The political cycle matters. BAPO is not commissioning this in the expectation that NHS England will immediately release new funding. It is commissioning it because the alternative, making the clinical case without the economic case, has not been sufficient.

What this means

When a professional association concludes that the clinical argument needs to be augmented by an economic argument, it reflects something real about where the conversation stands. Clinicians in the UK O&P field have been making the case for adequate provision in clinical terms for years. That case has not produced the results the field believes are warranted.

The economic analysis frames the argument differently. It does not ask whether prosthetics and orthotics represent good clinical practice; that is assumed. It asks whether the NHS can afford not to fund them adequately, and answers by quantifying what the current level of provision is costing downstream.

That is a different pressure point. Whether it is the right one, and whether DHSC and NHS England respond to it, is not a question the report can answer. BAPO has built the evidence base. What the system does with it is a separate calculation, and one that will take considerably longer than a budget cycle to resolve.

---

This article is based on publicly available reporting from The O&P EDGE and reflects general context about NHS O&P funding structures, health economic methodology, and the UK prosthetics and orthotics workforce. Specific findings from the BAPO independent economic analysis had not been published in full at time of writing. No medical or clinical guidance of any kind is provided or implied.